Median OS was similar in the sorafenib plus erlotinib and sorafenib plus placebo groups ( @ v @ months , respectively ; hazard ratio -LSB- HR -RSB- , @ ; P = @ ) , as was median time to progression ( @ v @ months , respectively ; HR , @ ; P = @ ) .